ProtaGene - About the company
ProtaGene is a series B company based in Heilbronn (Germany), founded in 2004 by Martin Blüggel. It operates as a Provider of drug development services for cell & gene therapeutic services. ProtaGene has raised $4.61M in funding. The company has 438 active competitors, including 106 funded and 51 that have exited. Its top competitors include companies like Oxford Instruments, Liquidia and FEI Company.
Company Details
- Website
- protagene.com
Key Metrics
Founded Year
2004
Location
Heilbronn, Germany
Stage
Series B
Total Funding
$4.61M in 2 rounds
Latest Funding Round
Investors
Ranked
102nd among 438 active competitors
Employee Count
132 as on Sep 30, 2026
Similar Companies
Legal entities associated with ProtaGene
ProtaGene is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ProtaGene CGT GmbH CIN: B1601_HRB719969 , Germany, Active | Jul 15, 2014 | - | - | |
ProtaGene GmbH CIN: HRB382627 , Germany, Active | Mar 22, 2004 | - | 108 (As on Dec 31, 2020) |
Sign up to download ProtaGene's company profile
ProtaGene's funding and investors
ProtaGene has raised a total funding of $4.61M over 2 rounds. Its first funding round was on Aug 15, 2012. ProtaGene has 2 institutional investors.
Here is the list of recent funding rounds of ProtaGene:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 02, 2013 | 4855825 | Series B | 7339406 | 5105566 | 4899375 | 2560380 |
Aug 15, 2012 | 1276733 | Seed | 6454213 | 9937601 | 9401775 | 5775148 |
View details of ProtaGene's funding rounds and investors
ProtaGene's founders and board of directors
Founder? Claim ProfileThe founders of ProtaGene is Martin Blüggel.
Here are the details of ProtaGene's key team members:
- Martin Blüggel: CEO, Founder of ProtaGene.
View details of ProtaGene's Founder profiles and Board Members
ProtaGene's employee count trend
ProtaGene has 132 employees as of Sep 26. Here is ProtaGene's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ProtaGene's Competitors and alternates
Top competitors of ProtaGene include Oxford Instruments, Liquidia and FEI Company. Here is the list of Top 10 competitors of ProtaGene, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Oxford Instruments 1959, High Wycombe (United Kingdom), Public | Manufacturer of scientific technology for atomic and molecular level research | - | 69/100 | |
2nd | Liquidia 2004, Morrisville (United States), Public | Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions | $90.3M | 68/100 | |
3rd | FEI Company 1971, Hillsboro (United States), Acquired | Electron microscopy solutions for advancing scientific discovery and industrial innovation | $300K | 65/100 | |
4th | Genedit 2016, Berkeley (United States), Series B | Developer of drug delivery system for genetic medicines | $93.5M | 65/100 | |
5th | Blue Rock Therapeutics 2016, Boston (United States), Acquired | Stem cell therapies for cardiovascular and neurological diseases | $225M | 62/100 | |
6th | Aera 2021, Boston (United States), Series B | Developer of genetic medicines across a wide range of therapeutic areas | $193M | 62/100 | |
7th | NanoSyrinx 2018, Coventry (United Kingdom), Series A | Developer of targeted intracellular delivery platform for biological molecules | $21.6M | 61/100 | |
8th | CRO focused on providing histopathology and genomics services | $7.5M | 59/100 | ||
9th | Helex 2021, New York City (United States), Seed | Provider of next-generation gene-editing therapies | $6M | 59/100 | |
10th | InnoMedica 2000, Bern (Switzerland), Acquired | Developer of therapeutics to treat cancer | $10.3M | - | 57/100 |
102nd | Provider of drug development services for cell & gene therapeutic services | $4.61M | 33/100 |
Looking for more details on ProtaGene's competitors? Click here to see the top ones
ProtaGene's Investments and acquisitions
ProtaGene has made no investments or acquisitions yet.
Reports related to ProtaGene
Here is the latest report on ProtaGene's sector:
News related to ProtaGene
•
ProtaGene appoints pharmaceutical industry leader Raymond Kaiser as Chief Executive Officer to drive next-generation growthPR Newswire•Sep 22, 2022•ProtaGene
•
ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as Chief Executive Officer to Drive Next Stages of GrowthPR Newswire•Sep 21, 2022•ProtaGene, Nexelis
•
New CRO ProtaGene to target analytics demand; plans for US testing facilityFierce Biotech•Jan 19, 2022•ProtaGene
•
Protagen Protein Services and BioAnalytix Merge to Create Global Analytic Service Partner for BiopharmaceuticalsGlobeNewswire•Apr 11, 2019•Protagen Protein Services, ProtaGene, BioAnalytix
Are you a Founder ?
FAQs about ProtaGene
Explore our recently published companies
- Way - Helsinki based, 2024 founded, Seed company
- Delite - Hyderabad based, 2010 founded, Unfunded company
- Yuki - Tel Aviv based, 2023 founded, Seed company
- Hedgepointcapital.com - 2021 founded, Funding Raised company
- MicroRoboTech - Hangzhou based, 2025 founded, Series A company
- Semper Plugins - Durham based, 2011 founded, Acquired company
